$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Guillain-Barre Syndrome - Pipeline Review, H1 2017
[Report Updated: 09-05-2017]

Published by Global Markets Direct: 09 May 2017 | 53495 | In Stock
Related Topics: Healthcare

Introduction

Guillain-Barre Syndrome - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2017, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.

Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 4 respectively. Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively.

Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Guillain-Barre Syndrome - Pipeline Review, H1 2017 [Report Updated: 09-05-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Guillain-Barre Syndrome - Overview

    Guillain-Barre Syndrome - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Guillain-Barre Syndrome - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Guillain-Barre Syndrome - Companies Involved in Therapeutics Development

    Akari Therapeutics Plc

    Annexon Inc

    CuraVac Inc

    Hansa Medical AB

    Regenesance BV

    Vitality Biopharma Inc

    Guillain-Barre Syndrome - Drug Profiles

    ANX-005 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Coversin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    immune globulin (human) - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit C6 for Guillain-Barre Syndrome - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaccine for Guillain-Barre Syndrome - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Guillain-Barre Syndrome - Dormant Projects

    Guillain-Barre Syndrome - Product Development Milestones

    Featured News & Press Releases

    Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome

    May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain-Barre Syndrome

    May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain-Barre Syndrome

    Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

    Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays

    Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

53495 | GMDHC9225IDB

Number of Pages

46

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Guillain-Barre Syndrome Global Clinical Trials Review, H2, 2017
Guillain-Barre Syndrome Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial re...
30 Aug 2017 by Global Data USD $2,500 More Info
Guillain-Barre Syndrome - Pipeline Insight, 2017
DelveInsight’s, “Guillain-Barre Syndrome-Pipeline Insights, 2017”, report provides comprehensive ins...
31 Jul 2017 by Delve Insight USD $1,250 More Info
Guillain-Barre Syndrome - Pipeline Insight, 2017
DelveInsight’s, “Guillain-Barre Syndrome-Pipeline Insights, 2017”, report provides comprehensive ins...
31 Jul 2017 by Delve Insight USD $1,250 More Info
Guillain - Epidemiology Forecast To 2023
DelveInsight “Guillain - Epidemiology Forecast To 2023” provides an overview of the epidemiology tre...
31 May 2017 by Delve Insight USD $2,750 More Info
Guillain-Barre Syndrome (GBS)-Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Guillain-Barre Syndrome (GB...
30 May 2017 by Delve Insight USD $4,950 More Info
Guillain-Barre Syndrome-Pipeline Insights, 2017
DelveInsight’s, “ Guillain-Barre Syndrome-Pipeline Insights, 2017”, report provides in depth insight...
30 May 2017 by Delve Insight USD $1,250 More Info
Malaysia Intravenous Immunoglobulin (IVIG) Market by Product Types (IgG, IgA, IgM, IgE and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Immune Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barré Syndrome, Kawasaki Disease,
CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS FOR STAKEHOLDERS1.3. KEY MARKET SEGME...
24 May 2017 by Allied Market Research USD $2,850 More Info
Guillain-Barre Syndrome Global Clinical Trials Review, H2, 2016
Guillain-Barre Syndrome Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial re...
21 Sep 2016 by Global Data USD $2,500 More Info
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2016
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial re...
30 Jun 2016 by Global Data USD $2,500 More Info
IVIG Market: By Application (Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome), By Route of Administration (Intravenous, Subcutaneous), By Geography-Forecast (2016-2021)
Immunoglobulin refers to the breakdown of blood plasma that contains antibody and Intravenous immuno...
26 Feb 2016 by USD $5,250 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Guillain-Barre Syndrome - Pipeline Review, H1 2017 [Report Updated: 09-05-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...